Holger Willenbring, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Holger Willenbring, MD, PhD

Associate Professor, Surgery, UCSF

Holger.Willenbring@ucsf.edu

Phone: (415) 476-2417
Box 0667, UCSF
San Francisco, CA 94143

UCSF Profiles

Cancer Center Membership

Associate Member » Developmental Therapeutics» Cancer Control

Education

Medical University, Lübeck, Germany, MD, 1996, Medicine
Medical University, Lübeck, Germany, PhD, 1999, Genetics
Harvard Medical School, Boston, MA, 1996, Medicine
University of Münster, Germany, 1996, Medicine


Professional Experience

  • 1997 - 1998
    Medical Intern, Department of Pediatrics, University of Münster, Germany
  • 1998 - 2001
    Medical Resident, Department of Pediatrics, University of Münster, Germany
  • 2001 - 2005
    Postdoctoral Fellow, Department of Molecular and Medical Genetics and Oregon Stem Cell Center, Oregon Health & Science University (OHSU), Portland, OR
  • 2005 - 2011
    Assistant Professor, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research and Department of Surgery, Division of Transplantation, UCSF
  • 2008 - present
    Enrichment Program Director, UCSF Liver Center, San Francisco, CA
  • 2011 - present
    Associate Professor, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research and Department of Surgery, Division of Transplantation, UCSF
  • 2012 - present
    Associate Director, UCSF Liver Center, San Francisco, CA

Honors & Awards

  • 2006-2009
    Liver Scholar Award of the American Liver Foundation (ALF) and the American Society of Transplantation (AST)
  • 2008-2013
    California Institute for Regenerative Medicine (CIRM) New Faculty Award

Selected Publications

  1. Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol. 2016 Dec; 7(6):819-827.
    View on PubMed
  2. Rezvani M, Español-Suñer R, Malato Y, Dumont L, Grimm AA, Kienle E, Bindman JG, Wiedtke E, Hsu BY, Naqvi SJ, Schwabe RF, Corvera CU, Grimm D, Willenbring H. In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis. Cell Stem Cell. 2016 Jun 2; 18(6):809-16.
    View on PubMed
  3. Rezvani M, Grimm AA, Willenbring H. Assessing the therapeutic potential of lab-made hepatocytes. Hepatology. 2016 Jul; 64(1):287-94.
    View on PubMed
  4. Desai SS, Tung JC, Zhou VX, Grenert JP, Malato Y, Rezvani M, Español-Suñer R, Willenbring H, Weaver VM, Chang TT. Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha. Hepatology. 2016 Jul; 64(1):261-75.
    View on PubMed
  5. Mattis AN, Song G, Hitchner K, Kim RY, Lee AY, Sharma AD, Malato Y, McManus MT, Esau CC, Koller E, Koliwad S, Lim LP, Maher JJ, Raffai RL, Willenbring H. A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver. Hepatology. 2015 Jan; 61(1):141-52.
    View on PubMed
  6. Hentzschel F, Hammerschmidt-Kamper C, Börner K, Heiss K, Knapp B, Sattler JM, Kaderali L, Castoldi M, Bindman JG, Malato Y, Willenbring H, Mueller AK, Grimm D. AAV8-mediated in vivo overexpression of miR-155 enhances the protective capacity of genetically attenuated malarial parasites. Mol Ther. 2014 Dec; 22(12):2130-41.
    View on PubMed
  7. Schaub JR, Malato Y, Gormond C, Willenbring H. Evidence against a stem cell origin of new hepatocytes in a common mouse model of chronic liver injury. Cell Rep. 2014 Aug 21; 8(4):933-9.
    View on PubMed
  8. Espejel S, Eckardt S, Harbell J, Roll GR, McLaughlin KJ, Willenbring H. Brief report: Parthenogenetic embryonic stem cells are an effective cell source for therapeutic liver repopulation. Stem Cells. 2014 Jul; 32(7):1983-8.
    View on PubMed
  9. Lee RH, Roll G, Nguyen V, Willenbring H, Tang Q, Kang SM, Stock PG. Failure to achieve normal metabolic response in non-obese diabetic mice and streptozotocin-induced diabetic mice after transplantation of primary murine hepatocytes electroporated with the human proinsulin gene (p3MTChins). Transplant Proc. 2014 Jul-Aug; 46(6):2002-6.
    View on PubMed
  10. Ng R, Wu H, Xiao H, Chen X, Willenbring H, Steer CJ, Song G. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology. 2014 Aug; 60(2):554-64.
    View on PubMed
  11. Zhu S, Rezvani M, Harbell J, Mattis AN, Wolfe AR, Benet LZ, Willenbring H, Ding S. Mouse liver repopulation with hepatocytes generated from human fibroblasts. Nature. 2014 Apr 3; 508(7494):93-7.
    View on PubMed
  12. Mitchell C, Willenbring H. Addendum: A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc. 2014; 9(6).
    View on PubMed
  13. Mathur A, Loskill P, Hong S, Lee J, Marcus SG, Dumont L, Conklin BR, Willenbring H, Lee LP, Healy KE. Human induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug development. Stem Cell Res Ther. 2013; 4 Suppl 1:S14.
    View on PubMed
  14. Lim L, Balakrishnan A, Huskey N, Jones KD, Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, Willenbring H, Dupuy A, Chen X, Brown D, Chang AN, Goga A. MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology. 2014 Jan; 59(1):202-15.
    View on PubMed
  15. Willenbring H, Soto-Gutierrez A. Transplantable liver organoids made from only three ingredients. Cell Stem Cell. 2013 Aug 1; 13(2):139-40.
    View on PubMed
  16. Ma X, Duan Y, Tschudy-Seney B, Roll G, Behbahan IS, Ahuja TP, Tolstikov V, Wang C, McGee J, Khoobyari S, Nolta JA, Willenbring H, Zern MA. Highly efficient differentiation of functional hepatocytes from human induced pluripotent stem cells. Stem Cells Transl Med. 2013 Jun; 2(6):409-19.
    View on PubMed
  17. Willenbring H, Grompe M. A therapy for liver failure found in the JNK yard. Cell. 2013 Apr 11; 153(2):283-4.
    View on PubMed
  18. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, Gores GJ, Dombrowski F, Evert M, Chen X, Willenbring H. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012 Aug; 122(8):2911-5.
    View on PubMed
  19. Mattis AN, Willenbring H. A ZFN/piggyBac step closer to autologous liver cell therapy. Hepatology. 2012 Jun; 55(6):2033-5.
    View on PubMed
  20. Ng R, Song G, Roll GR, Frandsen NM, Willenbring H. A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration. J Clin Invest. 2012 Mar; 122(3):1097-108.
    View on PubMed

Go to UCSF Profiles, powered by CTSI